GALT

Galectin Therapeutics Inc

Add to Watchlist

Advanced Chart

3.600

+0.3(9.091%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.750

Open

3.300

VWAP

3.63

Vol

590.50K

Mkt Cap

227.85M

Low

3.300

Amount

2.14M

EV/EBITDA(TTM)

Total Shares

63.29M

254.73M

EV/OCF(TTM)

P/S(TTM)

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

1 Analyst Rating

66.67% Upside

Wall Street analysts forecast GALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

66.67% Upside

Current: 3.600

Low

6.00

Averages

6.00

High

6.00

66.67% Upside

Current: 3.600

Low

6.00

Averages

6.00

High

6.00

H.C. Wainwright

Buy

initiated

2025-06-18

Reason

H.C. Wainwright

Price Target

2025-06-18

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Galectin Therapeutics with a Buy rating and $6 price target. Galectin's lead asset is belapectin, an intravenously administered galectin-3 inhibitor. Galectin-3 is a protein that plays a key role in cell signaling, differentiation, apoptosis, and inflammation, the analyst tells investors in a research note. The firm says that despite the company's setbacks, it believes "the stock can get back on track." It says belapectin is a "unique therapy targeting a clinically relevant molecule."

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-04-02

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-04-02

Reiterates

Hold

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Hold

Downgrades

n/a

2024-12-27

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2024-12-27

Downgrades

Strong Buy

Hold

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$11

2024-11-15

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$11

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$11

2024-08-16

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$11

2024-08-16

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Galectin Therapeutics Inc (GALT.O) is -4.96, compared to its 5-year average forward P/E of -3.01. For a more detailed relative valuation and DCF analysis to assess Galectin Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.01

Current PE

-4.96

Overvalued PE

-1.86

Undervalued PE

-4.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.04

Current PS

0.00

Overvalued PS

5.64

Undervalued PS

-3.55